GenSight Biologics: Publication of an article on the predictions of LUMEVOQ® gene therapy

GenSight Biologics has published an exploratory analysis of predictors of final visual outcome in patients treated with LUMEVOQ® for Leber Hereditary Optic Neuropathy (LHON). The study, published in Investigative Ophthalmology & Visual Science, identifies better initial visual acuity and retinal layer thickness as key predictors of improvement one and a half years after treatment. Additionally, treating patients during the dynamic phase of LHON may provide better visual outcomes than those treated during the subacute phase.

These findings could encourage bilateral treatment of NOHL patients, according to Dr. Robert C. Sergott, implying that direct injection of lenadogene nolparvovec could outweigh the contralateral therapeutic effect.